Overview

Management of Patent Ductus in Premature Infants

Status:
Completed
Trial end date:
1982-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the effects (up to one year of age) of indomethacin on the clinical course of patent ductus arteriosus (PDA) in premature infants (24 hours old or less) and to assess the relative merits of indomethacin and surgery in infants with persistent respiratory distress who were not treated early with indomethacin. Two concurrent trials were performed.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Indomethacin